{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T11:26:13Z","timestamp":1794137173810,"version":"4.8.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Triglyceride-rich lipoproteins (TRLs) and LDL remain major drivers of atherosclerotic cardiovascular disease, and angiopoietin-like protein 3 (ANGPTL3) has emerged as a promising target to lower both triglycerides and LDL cholesterol (LDL-C). This review provides an overview on ANGPTL3 inhibition, including genetic insights and clinical evidence, and examines patient groups in which therapies may be particularly well suited to reduce residual cardiovascular risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Genetic studies have shown that carriers of ANGPTL3 loss-of-function variants exhibit lower levels of triglycerides and LDL-C, and a reduced cardiovascular risk. Evinacumab, a monoclonal antibody targeting ANGPTL3, lowers LDL-C by approximately 50% in patients with homozygous familial hypercholesterolemia (HoFH), in whom traditional lipid-lowering therapies are largely ineffective. In patients with mixed dyslipidemia, small interfering RNAs (e.g. zodasiran and solbinsiran) and antisense oligonucleotides (e.g. vupanorsen) achieve approximately 60% triglyceride and 20% LDL-C lowering, with the small interfering RNAs having a generally favorable safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>ANGPTL3 inhibition offers an LDL receptor-independent means to lower atherogenic particles spanning from TRLs to LDL, complementing traditional lipid-lowering therapies. Evinacumab is practice-changing in HoFH, and RNA agents may soon broaden applicability to patients with mixed dyslipidemia and residual cardiovascular risk, pending cardiovascular outcomes trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mol.0000000000001013","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:00:10Z","timestamp":1762347610000},"page":"285-291","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Future of angiopoietin-like protein 3 inhibitors as a therapeutic agent"],"prefix":"10.1097","volume":"36","author":[{"given":"Nicholas A.","family":"Marston","sequence":"first","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Zimerman","sequence":"additional","affiliation":[{"name":"MOVE Academic Research Organization, Hospital Moinhos de Vento, Moinhos de Vento College of Health Sciences"},{"name":"Postgraduate Program in Cardiology and Cardiovascular Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"R1-20251105","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"New Engl J Med"},{"key":"R2-20251105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"key":"R3-20251105","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13023-018-0841-3","article-title":"Target achievement and cardiovascular event rates with Lomitapide in homozygous familial hypercholesterolaemia","volume":"13","author":"Blom","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"R4-20251105","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehae325","article-title":"Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy","volume":"45","author":"Gaudet","year":"2024","journal-title":"Eur Heart J"},{"key":"R5-20251105","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"New Engl J Med"},{"key":"R6-20251105","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jamacardio.2023.2921","article-title":"Longer-term efficacy and safety of evinacumab in patients with refractory hypercholesterolemia","volume":"8","author":"Rosenson","year":"2023","journal-title":"JAMA Cardiol"},{"key":"R7-20251105","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2019.05.004","article-title":"Low-density lipoprotein cholesterol goal achievement in patients with familial hypercholesterolemia in countries outside Western Europe: the International ChoLesterol management Practice Study","volume":"13","author":"Blom","year":"2019","journal-title":"J Clin Lipidol"},{"key":"R8-20251105","doi-asserted-by":"crossref","first-page":"117117","DOI":"10.1016\/j.atherosclerosis.2023.03.022","article-title":"LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: a sex and gender-specific analysis","volume":"384","author":"Schreuder","year":"2023","journal-title":"Atherosclerosis"},{"key":"R9-20251105","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMc2306575","article-title":"Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia","volume":"390","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"key":"R10-20251105","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","article-title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study","volume":"44","author":"Bj\u00f6rnson","year":"2023","journal-title":"Eur Heart J"},{"key":"R11-20251105","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jacc.2025.02.035","article-title":"Target populations for novel triglyceride-lowering therapies","volume":"85","author":"Nordestgaard","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"R12-20251105","doi-asserted-by":"crossref","first-page":"119235","DOI":"10.1016\/j.atherosclerosis.2025.119235","article-title":"Angiopoietin-like protein inhibitors: promising agents for the treatment of familial hypercholesterolemia and atherogenic dyslipidemia","volume":"405","author":"Vahdat-Lasemi","year":"2025","journal-title":"Atherosclerosis"},{"key":"R13-20251105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5603\/CJ.a2021.0006","article-title":"Angiopoietin-like proteins inhibitors: new horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia","volume":"30","author":"Surma","year":"2023","journal-title":"Cardiol J"},{"key":"R14-20251105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MOL.0000000000000979","article-title":"Emerging agents targeting triglycerides","volume":"36","author":"Prakash","year":"2025","journal-title":"Curr Opin Lipidol"},{"key":"R15-20251105","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1161\/CIRCULATIONAHA.124.069272","article-title":"Associations of circulating ANGPTL3, C-terminal domain\u2013containing ANGPTL4, and ANGPTL3\/8 and ANGPTL4\/8 complexes with LPL activity, diabetes, inflammation, and cardiovascular mortality","volume":"151","author":"Silbernagel","year":"2025","journal-title":"Circulation"},{"key":"R16-20251105","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J Lipid Res"},{"key":"R17-20251105","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/MOL.0000000000000755","article-title":"Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia","volume":"32","author":"Mohamed","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"R18-20251105","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/jamacardio.2025.0195","article-title":"Joint associations of APOC3 and LDL-C\u2013lowering variants with the risk of coronary heart disease","volume":"10","author":"Wang","year":"2025","journal-title":"JAMA Cardiol"},{"key":"R19-20251105","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N Engl J Med"},{"key":"R20-20251105","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"key":"R21-20251105","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","article-title":"Inactivating variants in ANGPTL4 and risk of coronary artery disease","volume":"374","author":"Dewey","year":"2016","journal-title":"N Engl J Med"},{"key":"R22-20251105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/MOL.0000000000000991","article-title":"Genetics of remnant cholesterol","volume":"36","author":"Wulff","year":"2025","journal-title":"Curr Opin Lipidol"},{"key":"R23-20251105","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1194\/jlr.RA120000781","article-title":"Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids","volume":"61","author":"Chen","year":"2020","journal-title":"J Lipid Res"},{"key":"R24-20251105","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of vupanorsen on non\u2013high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation"},{"key":"R25-20251105","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0140-6736(25)00507-0","article-title":"Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Ray","year":"2025","journal-title":"The Lancet"},{"key":"R27-20251105","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"R28-20251105","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","article-title":"Evinacumab for pediatric patients with homozygous familial hypercholesterolemia","volume":"149","author":"Wiegman","year":"2024","journal-title":"Circulation"},{"key":"R30-20251105","doi-asserted-by":"crossref","first-page":"120374","DOI":"10.1016\/j.atherosclerosis.2025.120374","article-title":"Zodasiran (ARO-ANG3), an investigational RNAi therapeutic, demonstrates profound and durable reductions in LDL-cholesterol, apolipoprotein B, and ANGPTL3 in patients with HoFH; gateway final results","volume":"407","author":"Raal","year":"2025","journal-title":"Atherosclerosis"},{"key":"R32-20251105","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.jacc.2025.03.008","article-title":"Angiopoietin-like 3 antibody therapy in patients with suboptimally controlled hyperlipidemia","volume":"85","author":"Xie","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"R33-20251105","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/eurjpc\/zwae090","article-title":"Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial","volume":"31","author":"Zimerman","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"R34-20251105","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"key":"R35-20251105","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/s41591-025-03830-4","article-title":"Targeting the angiopoietin-like protein 3\/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial","volume":"31","author":"Gaudet","year":"2025","journal-title":"Nat Med"},{"key":"R36-20251105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/MOL.0000000000000920","article-title":"ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?","volume":"35","author":"Chan","year":"2024","journal-title":"Curr Opin Lipidol"},{"key":"R37-20251105","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(25)00825-6","article-title":"Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b\/2a clinical studies","volume":"405","author":"Cummings","year":"2025","journal-title":"Lancet"},{"key":"R38-20251105","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 Randomized Clinical Trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"},{"key":"R39-20251105","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/j.jacl.2023.12.001","article-title":"Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3","volume":"18","author":"Zimerman","year":"2024","journal-title":"J Clin Lipidol"},{"key":"R40-20251105","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCULATIONAHA.123.065866","article-title":"ANGPTL3 deficiency and risk of hepatic steatosis","volume":"148","author":"D\u2019Erasmo","year":"2023","journal-title":"Circulation"},{"key":"R41-20251105","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/eurheartj\/ehad845","article-title":"Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk","volume":"45","author":"Gobeil","year":"2024","journal-title":"Eur Heart J"},{"issue":"Suppl 2","key":"R42-20251105","article-title":"An in vivo CRISPR base editing therapy to inactivate the ANGPTL3 gene: nomination of a development candidate for VERVE-201","volume":"43","author":"Khera","year":"2022","journal-title":"Eur Heart J"},{"issue":"8_Suppl","key":"R43-20251105","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0735-1097(23)01559-0","article-title":"Preclinical data supporting potential efficacy of verve-201 - an investigational crispr base editing medicine targeting angptl3 - in primary human cells, mice, and nonhuman primates","author":"Lee","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R44-20251105","article-title":"Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: a phase 2b trial","volume":"S1933-2874","author":"Rosenson","year":"2025","journal-title":"J Clin Lipidol"},{"key":"R45-20251105","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(25)00613-0","article-title":"Therapy for mixed dyslipidaemia through ANGPTL3 inhibition","volume":"405","author":"Santos","year":"2025","journal-title":"Lancet"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000001013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:00:15Z","timestamp":1762347615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000001013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000001013","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}